Healios K.K. (4593.T)
JPY 323.0
(0.94%)
JPY 323.0
(0.94%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -3.37 Billion JPY | 34.74% |
| 2022 | -5.17 Billion JPY | 3.81% |
| 2021 | -5.38 Billion JPY | -28.68% |
| 2020 | -4.18 Billion JPY | 2.04% |
| 2019 | -4.27 Billion JPY | 15.64% |
| 2018 | -5.06 Billion JPY | -115.61% |
| 2017 | -2.34 Billion JPY | 33.05% |
| 2016 | -3.5 Billion JPY | -230.76% |
| 2015 | -1.06 Billion JPY | -86.6% |
| 2014 | -568.29 Million JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -321 Million JPY | 69.34% |
| 2024 Q1 | -1.04 Billion JPY | 3.15% |
| 2023 Q4 | -1.08 Billion JPY | -45.3% |
| 2023 FY | -3.38 Billion JPY | 34.74% |
| 2023 Q2 | -666 Million JPY | 25.0% |
| 2023 Q1 | -888 Million JPY | 17.24% |
| 2023 Q3 | -744 Million JPY | -11.71% |
| 2022 Q1 | -1.42 Billion JPY | 5.56% |
| 2022 Q4 | -1.07 Billion JPY | -3.07% |
| 2022 FY | -5.17 Billion JPY | 3.81% |
| 2022 Q3 | -1.04 Billion JPY | 36.37% |
| 2022 Q2 | -1.63 Billion JPY | -14.57% |
| 2021 Q3 | -1.42 Billion JPY | -37.67% |
| 2021 FY | -5.38 Billion JPY | -28.68% |
| 2021 Q1 | -1.4 Billion JPY | -11.77% |
| 2021 Q2 | -1.03 Billion JPY | 26.12% |
| 2021 Q4 | -1.51 Billion JPY | -5.81% |
| 2020 FY | -4.18 Billion JPY | 2.04% |
| 2020 Q4 | -1.25 Billion JPY | -16.71% |
| 2020 Q3 | -1.07 Billion JPY | -17.32% |
| 2020 Q2 | -918 Million JPY | 1.29% |
| 2020 Q1 | -930 Million JPY | 25.36% |
| 2019 FY | -4.27 Billion JPY | 15.64% |
| 2019 Q2 | -1.01 Billion JPY | -2.52% |
| 2019 Q1 | -993 Million JPY | 3.59% |
| 2019 Q3 | -1.07 Billion JPY | -5.5% |
| 2019 Q4 | -1.24 Billion JPY | -16.01% |
| 2018 Q4 | -1.03 Billion JPY | -40.71% |
| 2018 FY | -5.06 Billion JPY | -115.61% |
| 2018 Q2 | -2.74 Billion JPY | -396.93% |
| 2018 Q1 | -553 Million JPY | -0.49% |
| 2018 Q3 | -732 Million JPY | 73.36% |
| 2017 Q1 | -490.23 Million JPY | -7.91% |
| 2017 Q4 | -550.3 Million JPY | 36.18% |
| 2017 Q2 | -445.39 Million JPY | 9.15% |
| 2017 Q3 | -862.28 Million JPY | -93.6% |
| 2017 FY | -2.34 Billion JPY | 33.05% |
| 2016 Q1 | -2.11 Billion JPY | -496.03% |
| 2016 FY | -3.5 Billion JPY | -230.76% |
| 2016 Q4 | -454.3 Million JPY | -0.92% |
| 2016 Q3 | -450.16 Million JPY | 7.77% |
| 2016 Q2 | -488.09 Million JPY | 76.92% |
| 2015 Q4 | -354.83 Million JPY | -84.58% |
| 2015 Q1 | -232.6 Million JPY | 0.0% |
| 2015 Q2 | -280.74 Million JPY | -20.7% |
| 2015 Q3 | -192.23 Million JPY | 31.53% |
| 2015 FY | -1.06 Billion JPY | -86.6% |
| 2014 FY | -568.29 Million JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 596.82 Million JPY | 666.165% |
| PRISM BioLab Co.,LTD | -496.86 Million JPY | -580.06% |
| GNI Group Ltd. | 13.1 Billion JPY | 125.776% |
| Linical Co., Ltd. | 725.72 Million JPY | 565.604% |
| Trans Genic Inc. | 89.43 Million JPY | 3878.121% |
| MEDINET Co., Ltd. | -1.42 Billion JPY | -136.964% |
| Soiken Holdings Inc. | -610 Million JPY | -453.928% |
| Cytori Cell Research Institute, Inc. | -772.74 Million JPY | -337.274% |
| AnGes, Inc. | -11.96 Billion JPY | 71.765% |
| OncoTherapy Science, Inc. | -1.12 Billion JPY | -201.481% |
| Nxera Pharma Co., Ltd. | -9.52 Billion JPY | 64.529% |
| Immuno-Biological Laboratories Co., Ltd. | 104.29 Million JPY | 3339.724% |
| NanoCarrier Co., Ltd. | -864.41 Million JPY | -290.9% |
| Carna Biosciences, Inc. | -1.11 Billion JPY | -202.513% |
| CanBas Co., Ltd. | -1.26 Billion JPY | -167.75% |
| D. Western Therapeutics Institute, Inc. | -798.55 Million JPY | -323.138% |
| RaQualia Pharma Inc. | -337.36 Million JPY | -901.586% |
| Chiome Bioscience Inc. | -1.2 Billion JPY | -180.376% |
| Kidswell Bio Corporation | -1.33 Billion JPY | -152.995% |
| PeptiDream Inc. | 6.77 Billion JPY | 149.889% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | -75.079% |
| Ribomic Inc. | -1.11 Billion JPY | -202.725% |
| SanBio Company Limited | -4.53 Billion JPY | 25.556% |
| BrightPath Biotherapeutics Co., Ltd. | -1.15 Billion JPY | -192.534% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | -142.481% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | -140.841% |
| StemRIM | -2.07 Billion JPY | -62.765% |
| CellSource Co., Ltd. | 1.22 Billion JPY | 376.627% |
| FunPep Company Limited | -994 Million JPY | -239.94% |
| Kringle Pharma, Inc. | -888.76 Million JPY | -280.192% |
| Stella Pharma Corporation | -760.3 Million JPY | -344.43% |
| TMS Co., Ltd. | -943.25 Million JPY | -258.228% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | -335.78% |
| Cuorips Inc. | -588.48 Million JPY | -474.184% |
| K Pharma,Inc. | 366.05 Million JPY | 1023.08% |
| Takara Bio Inc. | 3 Billion JPY | 212.521% |
| ReproCELL Incorporated | -409.29 Million JPY | -725.57% |
| PhoenixBio Co., Ltd. | 11.06 Million JPY | 30643.252% |
| StemCell Institute Inc. | 413.75 Million JPY | 916.659% |
| Japan Tissue Engineering Co., Ltd. | 144.5 Million JPY | 2438.295% |
| CellSeed Inc. | -697.77 Million JPY | -384.253% |